Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 09:06pm CET
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES 1.90% 80.91 Delayed Quote.10.83%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
02/24GILEAD SCIENCES : Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Agains..
AQ
02/24GILEAD SCIENCES : Fish & Richardson client prevails in reversal of $2.5 billion ..
AQ
02/23GILEAD SCIENCES' : Trademark Application for "SIMPLY POWERFUL" Filed
AQ
02/23GILEAD SCIENCES : An Application for the Trademark "AZLI" Has Been Filed by Gile..
AQ
02/23GILEAD SCIENCES : Trademark Application for "LETAIRIS" Filed by Gilead Sciences
AQ
02/22GILEAD SCIENCES : Announces Senior Management Change
BU
02/22SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/22GILEAD SCIENCES : Kite, a Gilead Company, And Sangamo Therapeutics Announce Coll..
PR
02/21GILEAD SCIENCES : Wired News - Gilead Sciences Rejoices as Federal Judge Reverse..
AC
More news
News from SeekingAlpha
02/23Gilead withdraws application in Europe for expanded use of Zydelig 
02/23YOUR DAILY PHARMA SCOOP : Dynavax Achieves Major Milestone, GW Pharmaceuticals G.. 
02/23SORRENTO THERAPEUTICS : Will This Novel CAR-T Deliver Robust Value? 
02/23U.S. BIOTECH/PHARMA SECTOR DAILY OBS : February 22, 2018 
02/22SANGAMO THERAPEUTICS : Great Start To 2018 - $3 Billion KITE Announcement 
Financials ($)
Sales 2018 21 270 M
EBIT 2018 11 296 M
Net income 2018 6 975 M
Debt 2018 16 887 M
Yield 2018 2,79%
P/E ratio 2018 15,36
P/E ratio 2019 14,46
EV / Sales 2018 5,75x
EV / Sales 2019 5,66x
Capitalization 105 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 88,8 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES10.83%105 375
VERTEX PHARMACEUTICALS5.16%39 931
REGENERON PHARMACEUTICALS-16.00%34 113
BIOVERATIV INC93.43%11 243
GENMAB16.62%10 343
BLUEBIRD BIO INC12.97%10 168